New HIV-inhibiting protein identified
Scientists have identified a new HIV-suppressing protein in the blood of people infected with the virus. In laboratory studies, the protein, called CXCL4 or PF-4, binds to HIV such that it cannot attach to or enter a human cell. The research was led by Paolo Lusso, M.D., Ph.D., chief of the Section of Viral Pathogenesis in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH.
CXCL4 belongs to a family of molecules called chemokines that help regulate the movement of immune cells around the body. In the mid-1990s, four chemokinesthree discovered by Dr. Lusso, Robert Gallo, M.D., and their colleagueswere found in laboratory experiments to function as HIV inhibitors. These chemokines as well as CXCL4 may regulate the level of virus replication in infected individuals and thus the pace at which HIV disease progresses.
According to Dr. Lusso, the site where CXCL4 binds to the outer coat of HIV seems to be different from other known vulnerable sites targeted by HIV-blocking antibodies and drugs. His team is working with scientists at the NIAID Vaccine Research Center to define the atomic-level crystal structure of this binding site, which potentially may play a role in the future development of HIV treatments or vaccines.
CXCL4 differs from the other four major HIV-suppressive chemokines in several respects. The other four chemokines inhibit HIV infection by binding to either one of two cell receptorscalled CCR5 and CXCR4used by the virus to attach to and enter immune cells, whereas CXCL4 binds directly to the outer surface of the virus. While the other chemokines bind to forms of HIV that use either the CCR5 or the CXCR4 receptor, CXCL4 can bind to and block infection by a wide variety of HIV strains, no matter what their receptor specificity. Finally, while the other chemokines are made primarily by immune cells, CXCL4 is made by platelets, the blood cells involved in clotting.
Dr. Lusso and his colleagues are pursuing further research to better understand CXCL4's role in HIV disease and to determine whether the chemokine has a protective effect not only in laboratory studies, but also in people.
More information: DJ Auerbach et al., Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor. PNAS DOI: 10.1073/pnas.1207314109 (2012).
Journal reference: Proceedings of the National Academy of Sciences
- Scientists identify new cellular receptor for HIV Feb 10, 2008 | not rated yet | 0
- Researchers discuss challenges to developing broadly protective HIV vaccines Sep 07, 2011 | not rated yet | 0
- Scientists reactivate immune cells exhausted by chronic HIV Jun 03, 2011 | not rated yet | 0
- Researchers determine how antibody recognizes key sugars on HIV surface Nov 23, 2011 | not rated yet | 0
- Scientists find another key to HIV success Mar 22, 2006 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011 I'd like to open a discussion thread for version 2 of the draft of my book ''Classical and Quantum Mechanics via Lie algebras'', available online at http://lanl.arxiv.org/abs/0810.1019 , and for the...
- More from Physics Forums - Independent Research
More news stories
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
HIV & AIDS 23 hours ago | 5 / 5 (3) | 0 |
Detection of HIV antibodies is used to diagnose HIV infection and monitor trials of experimental HIV/AIDS vaccines. New, more sensitive detection systems being developed use microspheres to capture HIV antibodies ...
HIV & AIDS May 23, 2013 | 5 / 5 (1) | 0
(HealthDay)—For HIV-infected individuals with recurrent Clostridium difficile infection, fecal microbiota therapy is feasible, according to a letter published in the May 21 issue of the Annals of Intern ...
HIV & AIDS May 22, 2013 | not rated yet | 0
Canadian health authorities lifted Wednesday what was effectively a ban on gay men giving blood, announcing new rules making men who have not had sex with men in the past five years eligible.
HIV & AIDS May 22, 2013 | not rated yet | 1
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
1 hour ago | not rated yet | 4
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
1 hour ago | not rated yet | 1
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
1 hour ago | not rated yet | 0
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
1 hour ago | not rated yet | 0
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
20 hours ago | 3.7 / 5 (3) | 2 |
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
18 hours ago | 3 / 5 (2) | 0 |